Takeaways: The approval of Nduvra (tapinarof) 1% for moderate to severe atopic dermatitis gives Organon a first‑in‑class, steroid‑free topical that can be prescribed by family physicians w...
Takeaways: The pCPA Letter of Intent for Anzupgo (delgocitinib cream) moves Canada closer to public reimbursement for the first topical therapy specifically indicated for moderate to severe chro...
Takeaways: Alberta’s coverage broadens Elidel’s public-access footprint in Canada and should make it easier for dermatologists to use a non-corticosteroid topical when conventional therapies are...
